Last reviewed · How we verify
Abdominal wall injections with lidocaine 2%
Abdominal wall injections with lidocaine 2% is a Small molecule drug developed by Oregon Health and Science University. It is currently FDA-approved.
Abdominal wall injections with lidocaine 2%, marketed by Oregon Health and Science University, hold a niche position in the local anesthetic market. The key composition patent, set to expire in 2028, provides a significant barrier to entry for generic competitors. The primary risk is the potential for increased competition once the patent expires.
At a glance
| Generic name | Abdominal wall injections with lidocaine 2% |
|---|---|
| Sponsor | Oregon Health and Science University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Intrathecal MoRphine Versus Transabdominal Plane Block (TAP) Block for AnalGesic Management in Elective Caesarean Section (PHASE4)
- Compared With Different Method for Postcesarean Section Analgesia (NA)
- Effect of Abdominal Wall Injections on Abdominal Pain (PHASE4)
- A Comparison of Two Regional Techniques for Bariatric Sleeve Gastrectomy (NA)
- Administration of Platelet-rich Fibrin to Autologous Fat Tissue in Injection Laryngoplasty for Vocal Cord Paralysis (PHASE4)
- Quadratus Lumborum Block (Transmuscular Approach) VS. TransversusAbdominus Plane Block(Unilateral Posterior Approach) for Perioperative Analgesia in Patients Undergoing Flank Incision Surgeries. (NA)
- Comparison Study of Transversus Abdominal Plane, Paravertebral and Epidural Blocks in Laparoscopic Colectomy (NA)
- Ultrasound Guided Subcostal Transversus Abdominis Plane Versus Paravertebral Block in the Laparoscopic Cholecystectomy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Abdominal wall injections with lidocaine 2% CI brief — competitive landscape report
- Abdominal wall injections with lidocaine 2% updates RSS · CI watch RSS
- Oregon Health and Science University portfolio CI